Teclistamab Injection
-
【招募中】Teclistamab Injection - 免费用药（一项在复发或难治性多发性骨髓瘤受试者中比较Teclistamab单药治疗与泊马度胺、硼替佐米、地塞米松(PVd)或卡非佐米、地塞米松(Kd)的研究）
Teclistamab Injection的适应症是复发性或难治性多发性骨髓瘤。 此药物由Janssen Research & Development， LLC/ 强生（中国）投资有限公司/ Patheon Manufacturing Services LLC/ Janssen Research & Development, A division of Janssen Pharmaceutica NV; Fisher Clinical Services, Inc.； Fisher Clinical Services GmbH; Fisher Clinical Services UK Limited; Fisher Bioservices; Fisher Clinical Services; Clinigen Clinical Supplies Management SA; Catalent Germany Schorndorf GmbH; Catalent CTS, LLC; Catalent Pharma Solutions, LLC;/ Janssen Research & Development, A division of Janssen Pharmaceutica NV；Fisher Clinical Services, Inc.； Fisher Clinical Services GmbH； Fisher Clinical Services UK Limited； Fisher Bioservices； Fisher Clinical Services; Clinigen Clinical Supplies Management SA; Catalent Germany Schorndorf GmbH; Catalent CTS, LLC; Catalent Pharma Solutions, LLC;/ Janssen Research & Development, A division of Janssen Pharmaceutica NV； Fisher Clinical Services, Inc.； Fisher Clinical Services GmbH； Fisher Clinical Services UK Limited； Fisher Bioservices； Fisher Clinical Services; Clinigen Clinical Supplies Management SA; Catalent Germany Schorndorf GmbH; Catalent CTS, LLC; Catalent Pharma Solutions, LLC;生产并提出实验申请，[实验的目的] 通过PFS评估，比较Teclistamab单药治疗与研究者选择的PVd或Kd的疗效
-
【招募已完成】Teclistamab Injection免费招募（Teclistamab治疗复发或难治性多发性骨髓瘤的临床研究）
Teclistamab Injection的适应症是恶性血液病 此药物由Janssen Research & Development， LLC/ 强生（中国）投资有限公司/ Patheon Manufacturing Services LLC/ Janssen Research & Development, A division of Janssen Pharmaceutia NV； Fisher Clinical Services, Inc.； Fisher Clinical Services GmbH； Fisher Clinical Services UK Limited； Fisher Bioservices； Fisher Clinical Services/ Janssen Research & Development, LLC生产并提出实验申请，[实验的目的] 试验目的是评估Teclistamab以Ⅱ期临床研究推荐剂量给药在复发或难治性多发性骨髓瘤患者中的疗效
